By Ademola Osigbesan, Robert Matiru, Kehinde Onasanya and Janet Ginnard (Unitaid); Ikechukwu Amamilo, James Conroy, Alya Omar and Carolyn Amole (Clinton Health Access Initiative); and Aayush Solanki and Karin Hatzold (Populations Services International).
This journal article was first published in ScienceDirect.
Low-and middle-income countries account for a significant proportion of the burden of disease for communicable illnesses globally, with malaria, tuberculosis and HIV and AIDS being the leading causes of death. Despite this disparity, low- and middle-income countries often have limited or delayed access to newer optimal health products compared to high-income countries. This limitation in access, driven by a myriad of barriers, undermines the potential health benefits that could be gained in low- and middle-income countries through the introduction of better health products.
To improve this inequity, governments in high-income countries, nongovernmental organizations and pharmaceutical companies often resort to establishing donation programs for low- and middle-income countries to circumvent some of the access barriers. While well-implemented donation programs have the potential to improve access to new products, poorly executed donation programs are common. These often have negative effects such as: over-reliance on donations by recipient countries; dumping of short-dated or unwanted products; costs of waste disposal where unsuitable or excess products are received; and a lack of focus on access sustainability planning.
Unitaid’s Early Market Access Vehicle (EMAV) is an innovative, demand-driven access model for introducing new optimal health commodities in low- and middle-income countries. An EMAV entails a conditional purchase commitment to the manufacturer for a defined quantity of selected products in exchange for a set of access commitments, required to facilitate equitable access in the target markets. EMAVs are designed to link catalytic donations to pathways for sustainable access.
Unitaid, in collaboration with its partners, has leveraged the EMAV to introduce two innovative health products in a number of low- and middle-income countries. This article discusses the EMAV model and builds the case on why stakeholders working on new product access should consider this approach as an alternative to traditional donation programs.
Read the full journal article here.
